Published On: Sat, Dec 1st, 2012

Investigational Multi-Drug Resistant Tuberculosis drug Bedaquiline gets backing from FDA panel

Johnson & Johnson said that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) ruled that its experimental treatment for multidrug-resistant tuberculosis appears to be safe and effective, according to a company news release Nov. 28.



The FDA panel in a unanimous vote (18-0), agreed that the efficacy findings for  investigational bedaquiline support the proposed indication for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The committee agreed in a vote of 11-7 that the safety findings supported the proposed indication.

The FDA is not required to follow the panel’s advice, though it often does.

Wim Parys, Global Head of Development, Infectious Diseases and Vaccines, Janssen said, “We are pleased with the committee’s recommendation and look forward to working with the FDA to bring this important therapy to patients who suffer from MDR-TB.

“The positive recommendation from the FDA advisory committee is an important step toward achieving that goal.”

The FDA has agreed to evaluate the drug under its priority review system, which aims to decide whether to approve an application within six months, rather than the standard 10 months.

Bedaquiline would be the first drug specifically for multidrug-resistant tuberculosis, and the first new type of TB drug in more than four decades, according to a CNBC report.

Read more about Multidrug-Resistant Tuberculosis (MDR TB)

For more infectious disease news and information, visit and “like” the Infectious Disease News Facebook page

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required

About the Author

- Writer, Co-Founder and Executive Editor of The Global Dispatch. Robert has been covering news in the areas of health, world news and politics for a variety of online news sources. He is also the Editor-in-Chief of the website, Outbreak News Today and hosts the podcast, Outbreak News Interviews on iTunes, Stitcher and Spotify Robert is politically Independent and a born again Christian Follow @bactiman63

Displaying 1 Comments
Have Your Say
  1. Janssen Therapeutic’s ‘Sirturo’ receives FDA approval for treatment of multi-drug resistant pulmonary tuberculosis - The Global Dispatch says:

    […] a follow-up to a Dec. 1 story, Janssen Therapeutics has announced the U.S. Food and Drug Administration (FDA) has granted […]

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Sign up for our Weekly Newsletter



At the Movies

Pin It